Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.

Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CC, Sobel RA, Cree BA, Schulze-Topphoff U, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 21;3(5):e272.

2.

Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity.

Pikor NB, Prat A, Bar-Or A, Gommerman JL.

Front Immunol. 2016 Jan 13;6:657. doi: 10.3389/fimmu.2015.00657. Review.

3.

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.

Wuhrer M, Selman MH, McDonnell LA, Kümpfel T, Derfuss T, Khademi M, Olsson T, Hohlfeld R, Meinl E, Krumbholz M.

J Neuroinflammation. 2015 Dec 18;12:235. doi: 10.1186/s12974-015-0450-1.

4.

MOG-induced experimental autoimmune encephalomyelitis in the rat species triggers anti-neurofascin antibody response that is genetically regulated.

Flytzani S, Guerreiro-Cacais AO, N'diaye M, Lindner M, Linington C, Meinl E, Stridh P, Jagodic M, Olsson T.

J Neuroinflammation. 2015 Oct 29;12:194. doi: 10.1186/s12974-015-0417-2.

5.
6.

γ-Secretase directly sheds the survival receptor BCMA from plasma cells.

Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, Wanngren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister HW, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E.

Nat Commun. 2015 Jun 11;6:7333. doi: 10.1038/ncomms8333.

7.

Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Bonnan M.

Mult Scler Int. 2015;2015:296184. doi: 10.1155/2015/296184. Review.

8.

The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity.

Hoffmann FS, Kuhn PH, Laurent SA, Hauck SM, Berer K, Wendlinger SA, Krumbholz M, Khademi M, Olsson T, Dreyling M, Pfister HW, Alexander T, Hiepe F, Kümpfel T, Crawford HC, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E.

J Immunol. 2015 Jan 15;194(2):542-52. doi: 10.4049/jimmunol.1402070.

9.

The Charcot Lecture | beating MS: a story of B cells, with twists and turns.

Hauser SL.

Mult Scler. 2015 Jan;21(1):8-21. doi: 10.1177/1352458514561911. Review.

10.

Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.

Claes N, Dhaeze T, Fraussen J, Broux B, Van Wijmeersch B, Stinissen P, Hupperts R, Hellings N, Somers V.

PLoS One. 2014 Oct 31;9(10):e111115. doi: 10.1371/journal.pone.0111115.

11.

A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected].

Miyazaki Y, Li R, Rezk A, Misirliyan H, Moore C, Farooqi N, Solis M, Goiry LG, de Faria Junior O, Dang VD, Colman D, Dhaunchak AS, Antel J, Gommerman J, Prat A, Fillatreau S, Bar-Or A; CIHR/MSSC New Emerging Team Grant in Clinical Autoimmunity.; MSSRF Canadian B cells in MS Team..

PLoS One. 2014 Aug 19;9(8):e105421. doi: 10.1371/journal.pone.0105421. Erratum in: PLoS One. 2014;9(9):e109041.

12.

Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis.

Khsheibun R, Paperna T, Volkowich A, Lejbkowicz I, Avidan N, Miller A.

PLoS One. 2014 Jul 15;9(7):e102331. doi: 10.1371/journal.pone.0102331.

13.

CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis.

Cantor JM.

J Neuroimmunol. 2014 Sep 15;274(1-2):230-3. doi: 10.1016/j.jneuroim.2014.06.015.

14.

Teriflunomide and its mechanism of action in multiple sclerosis.

Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H.

Drugs. 2014 Apr;74(6):659-74. doi: 10.1007/s40265-014-0212-x. Review.

15.
16.

Nogo-receptor 1 deficiency has no influence on immune cell repertoire or function during experimental autoimmune encephalomyelitis.

Litwak SA, Payne NL, Campanale N, Ozturk E, Lee JY, Petratos S, Siatskas C, Bakhuraysah M, Bernard CC.

PLoS One. 2013 Dec 5;8(12):e82101. doi: 10.1371/journal.pone.0082101.

17.

MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies.

Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil SS.

J Exp Med. 2013 Dec 16;210(13):2921-37. doi: 10.1084/jem.20130699.

18.

Cerebrospinal-fluid-derived immunoglobulin G of different multiple sclerosis patients shares mutated sequences in complementarity determining regions.

Singh V, Stoop MP, Stingl C, Luitwieler RL, Dekker LJ, van Duijn MM, Kreft KL, Luider TM, Hintzen RQ.

Mol Cell Proteomics. 2013 Dec;12(12):3924-34. doi: 10.1074/mcp.M113.030346.

19.

Specific peripheral B cell tolerance defects in patients with multiple sclerosis.

Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M, Preston-Hurlburt P, Herold KC, Hafler DA, O'Connor KC, Meffre E.

J Clin Invest. 2013 Jun;123(6):2737-41. doi: 10.1172/JCI68775.

20.

Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity.

Martinez-Pasamar S, Abad E, Moreno B, Velez de Mendizabal N, Martinez-Forero I, Garcia-Ojalvo J, Villoslada P.

BMC Syst Biol. 2013 Apr 26;7:34. doi: 10.1186/1752-0509-7-34.

Items per page

Supplemental Content

Support Center